Vir Biotechnology Reports Q1 Financial Results, Highlights Immunity-Boosting Technology Advancements

Vir Biotechnology, Inc. (Nasdaq: VIR) announced that it will be providing a corporate update and reporting financial results for the first quarter of 2024, ending on March 31, 2024, on May 2, 2024. The company will be hosting a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on May 2, 2024. The information will be shared through a press release after the market closes and will be accessible on the Vir website under Press Releases in the Investors section at www.vir.bio. Participants can join the conference call via webcast on the Events & Presentations page on Vir’s website or by dialing the U.S. toll-free number (888) 800-8770 or international +1 (646) 307-1953, Conference ID: 756877. A recorded version of the call will be available on the website approximately two hours after the event and will be archived there for 30 days.

Vir Biotechnology, Inc., headquartered in St Louis, Missouri is an immunology company dedicated to transforming lives through its research and development efforts in modulating immune systems to treat infectious diseases and other serious conditions such as cancer and autoimmune disorders. The company’s two technology platforms aim to empower the immune system to fight against pathogens by leveraging natural immune processes such as cytokine storm control and antigen presentation enhancement. Its current clinical development pipeline includes product candidates targeting hepatitis delta and hepatitis B viruses, as well as human immunodeficiency virus (HIV). Additionally, they have various preclinical candidates in their pipeline such as those targeting influenza A and B, COVID-19, RSV/MPV, HPV among others which are aimed at preventing or treating infectious diseases and cancer while also improving autoimmune disorder treatment outcomes